Prolonged life expectancy in the 20th century has been one of humankind's greatest triumphs. However, the substantial increase in the human life span has ushered in a new concern: healthy aging. Because infectious diseases prominently contribute to morbidity in the particularly vulnerable elderly population, strategies for preventing these diseases would have a clear impact on improving healthy aging. Thus, vaccines and immunization strategies tailored for the elderly population are needed, and vaccines should be developed to take into consideration the peculiar age-induced variations of immune responsiveness. The conference "Ageing and Immunity" recently held in Siena, Italy, has reviewed and discussed several possible causes of immune senescence, as well as strategies for counteracting this waning of immune responsiveness and for restoring immunocompetence. In addition, examples of diseases that should be targeted by vaccination in the senior population were considered.
ENSURING HEALTHY AGING
Improved sanitary conditions and progress in medical care have greatly prolonged human life expectancy, but these changes have led to a rapid aging of the world population, both in developed and developing countries. By the year 2030, the percentage of the population that will be elderly (≥60 years of age) is predicted to be over 25% of the total population, of which 75% will be living in less developed countries. Maintaining this population in healthy conditions therefore represents a major public health challenge.
Aging enhances susceptibility to severe infections, which represent a major cause of morbidity and mortality in the elderly population. T erefore, preventing infectious diseases is one of the necessary steps toward healthy aging. T e preventive strategies (vaccines) that are currently used and are ef ective in controlling many infectious diseases may not be suited for treating the elderly population because the aged immune system does not react with the same rules as that of a younger adult. To this end, a thorough investigation of the features of aging immune reactivity will be necessary, both in healthy and pathological or frailty conditions, so as to custom design vaccination and therapeutic strategies that can be maximally ef ective without increasing side ef ects. T us, inasmuch as aging represents one of the main health problems of the 21st century, vaccines specif cally directed to the elderly become a public health priority both in developed and developing countries.
AN AGING IMMUNE SYSTEM
T e second conference on "Ageing and Immunity, " held in Siena, Italy, 22 to 24 April 2012, was organized by Fondation Mérieux to review the progress made in the last 2.5 years af er the previous 2009 workshop (1) . A series of critical issues has been identif ed and addressed in order to set a framework for a more thorough understanding of immune senescence and for a targeted approach to ensure healthy aging to the human population.
A new baseline. T e metabolic changes of the aging body, including the increased presence of apoptotic cells and of oxidative stress, even in healthy conditions, induce the immune system to change its "quiescent" state to a dif erent, of en higher level of basal activation. Consequently, the immune reactivity of healthy elderly people is qualitatively and quantitatively dif erent from that of healthy adults. T us, dif erent "normal" thresholds should be considered in the healthy aging population. By identifying the features of the normal response by the aging immune system, it would then be possible to better identify pathological responses. Progress in understanding the cellular and molecular basis of immune senescence and immune responsiveness in the elderly will allow us to develop a better targeted and ef ective immunization strategy.
Combating immunological aging. D i f e rences in immune responses in aged individuals of en lead to a state of immunological frailty or immunosenescence. Immunological frailty can be addressed through diverse strategies, including preventing infectious diseases (vaccination), ensuring adequate nutrition and physical exercise, and maintaining a high level of intellectual challenge. However, implementation of such measures is a problem of resources and of public health strategies, in particular in less developed countries.
Vaccination in the elderly. T e r e i s e v idence that vaccination in the elderly delays the transition from so-called "young-old" to "old-old. " However, it remains dif cult to identify which age groups within the elderly population should be particularly targeted by vaccination. Reliable and robust biomarkers of vaccine-induced protection in the elderly (correlates of protective immunity) are needed. In addition, immune reactivity of the elderly to vaccination should be improved without triggering potentially adverse inf ammatory reactions. By integrating the progress made in understanding the molecular basis of immune senescence with vaccinology and gerontology, current scientif c knowledge could be translated into the development of vaccination strategies for the poorest countries.
THE BURDEN OF INFECTIOUS DISEASES IN THE ELDERLY
Infectious diseases are a major cause of morbidity and mortality in the elderly population. T ere are many reasons for this increased susceptibility. Inadequate response to infectious agents is not only caused by immune senescence but can be caused by malnutrition, which has a powerful immunosuppressive ef ect, by less ef ective barriers (such as more permeable skin, less mucus and saliva, and less active muscles), by concomitant chronic medical conditions, and by the increased use of medications. Malnutrition is a critical concern in the elderly population in developing countries, such as in Africa, where between 10 and 50% of the aged population has a body mass index (BMI) of <20, as opposed to 6% in Switzerland. T e risk of death from infectious disease in people over 70 years of age has been calculated to be minimal with a BMI of 25 to 30; however, this risk increases greatly in people over 70 with a BMI of <20 (2) . Within developed countries, infections variably af ect the elderly depending on the AGING environment (for example, nursing homes versus hospitals versus communities, season, or sex). In these populations, infections mainly consist of urinary and respiratory tract infections and pneumonia, pertussis, Helicobacter pylori-dependent gastritis, and reactivation of varicella zoster virus (VZV). Also important are periodontal infections; incidence is increased by the age-impaired salivation and oral functions. Periodontal infections can contribute to systemic cardiovascular and respiratory diseases (3) and, by causing tooth loss, contribute to inducing malnutrition. T ese interrelated causes contribute to defects at every level of the immune response and thus to an increase in infectious disease burden in the elderly.
DIFFERENCE IN THE IMMUNE RESPONSE IN THE ELDERLY
Innate immunity and inf ammation. T e r e l atively nonspecif c innate immune response, and its ef ector cells such as macrophages, polymorphonuclear leukocytes, and natural killer cells, is generally considered less prone to immune senescence than are mechanisms and ef ectors of adaptive immunity. However, most of the data supporting this perception have been generated in mice. By evaluating the available data on innate responses in aging humans, it is evident that several innate activities are also affected by old age; these dif erences result in a decreased capacity in immediate defense against pathogens and in reduced ability to initiate adaptive immunity, together with enhanced inf ammatory reactions (4, 5) . For example, polymorphonuclear leukocytes show age-related defects (5-7). In particular, response to chemotactic stimuli and inf ltration of inf amed tissues is impaired, as well as production of reactive oxygen species and intracellular killing capacity, with slower and less ef cient resolution of the infectious event. T e changes in innate responses appear to be in part due to intrinsic "senescence" that compromises the activation pathways, but they are in large part due to the changes occurring in the aging body and to the concurring infectious diseases.
Antigen-presenting cells. Responsiveness to vaccines depends among other factors on the capacity of antigen-presenting cells, such as dendritic cells (DCs), to take up and adequately present the vaccine to T cells and to trigger a protective response. Recent evidence shows that both myeloid (mDC) and plasmacytoid (pDC) DC populations are constitutively activated (in terms of intracellular cytokine production) in older (≥65 years of age), compared with young (age 21 to 30 years) adults (8) . T e constitutively inf ammatory microenvironment (inf ammaging) causes an increased "basal" level of innate/inf ammatory activation and may lead to enhanced inf ammation-dependent tissue damage during infections (9) . However, it may also cause an increased activation of down-regulatory mechanisms that may result in inadequate response to infectious challenges. T e role of DCs in inducing immunological tolerance also appears to be affected in old age, with consequent increase of the incidence of autoimmune diseases [reviewed in (10) ].
Toll-like receptor (TLR) stimulation, which strongly activates DCs from younger individuals, does not substantially augment cytokine production in old DCs. T e decreased in TLR signaling in old age has been proposed to be caused by decreased TLR expression (somewhat controversially) or to unresponsiveness of TLR to challenge [reviewed in (6) ]. T e latter may be a direct ef ect of aging (decreased functionality of the signaling pathway) or it could be due to an anti-inf ammatory rebound-increased expression of regulatory molecules, such as TIR8/SIGIRR and interleukin 37 (IL-37)-caused by the abundance of endogenous inf ammatory stimuli in the aging organism. Recent data suggest that aging can af ect the expression of microRNA (miRNA) regulating the activation of the nuclear factor κB inf ammatory pathway in mDCs, contributing to the decreased TLR-dependent DC activation (11) . Besides impaired TLR-dependent cytokines, old DCs and old monocytes also show decreased TLR-dependent expression of the costimulatory molecule CD80, two markers associated with protective response to inf uenza vaccination (8, 12) . T e s e d a t a suggest that improving vaccine ef cacy in the elderly may need to include strategies for increasing TLR responsiveness in DCs (Fig. 1) .
T cell responses. T e most evident changes in immune mechanisms during aging are those in adaptive immune mechanisms (Fig.  1) . Defense against intracellular infections is chief y mediated by T cells. By examining the dif erent T cell subsets, several defects can be identif ed that eventually af ect adaptive immunity, including the ability of naïve old T cells to activate, proliferate, and dif erentiate into robust ef ector cells; the ability of homeostatic mechanisms to maintain and preserve T cell subset balance; and the ability to mount an immune response while dealing with a latent persistent infection [for example, herpesviruses such as cytomegalovirus (CMV)] (13, 14) .
Alterations in signaling pathways in aging CD4 T cells are linked to decreased responsiveness to infections and impaired generation of protective immunity to vaccines. For example, T cell receptor (TCR) signaling is altered in old CD4 T cells. Although TCR expression is apparently unaffected, TCR-dependent extracellular signalregulated kinase (ERK) phosphorylation is reduced in parallel to a posttranscriptional increase in the phosphatase DUSP6 (which inhibits ERK). T e increase of DUSP6 is due to the age-dependent decline in miR181a, which controls DUSP6 expression (15) . Reconstitution of miR181a levels, or transcriptional silencing/pharmacological inhibition of DUSP6, markedly improves responsiveness of elderly CD4 T cells, including T helper cell (T H 1) dif erentiation.
In another example, upon activation aged CD4 memory T cells exhibit increased levels of DUSP4, another phosphatase that curtails the nuclear activity of phosphorylated ERK and c-Jun N-terminal kinase (JNK) (16) . T e increased transcription of DUSP4 is due to lower energy production and increased 5′ adenosine monophosphate-activated protein kinase (AMPK) activity. Silencing of DUSP4 expression in elderly CD4 T cells restores their ability to provide helper activity for B cell dif erentiation and antibody production (16) . T e identif cation of activated negativefeedback loops involving several members of the DUSP family in aged CD4 T cells opens the opportunity that signaling pathways in T cells can be directly targeted so as to optimize vaccine responses in the elderly.
Antiviral protection is mainly mediated by CD8 T cells, another T cell subset that is greatly af ected in the elderly. Aging leads to a shif in the CD8 T cell repertoire from naïve to highly dif erentiated CD28-negative ef ector memory T cells. T is shif is accelerated by latent infection with cytomegalovirus. An important issue that needs to be clarif ed is the mechanism by which the accumulation of end-dif erentiated ef ectors occurs, whether by continuous regeneration or impaired elimination (resistance to apoptosis). T e latter does not appear to be the case because indeed highly dif erentiated CD8 ef ector memory T cells in the old are particularly susceptible to induction of apoptosis but can be rescued from apoptosis by IL-15 (17) . T us, organs such as the bone marrow that produce increased levels of ILon May 16, 2013 stm.sciencemag.org Downloaded from 15 in old age are niches rich in dif erentiated CD8 ef ector memory T cells that can compensate for the senescence-dependent impairment of regenerative capacity (18) .
T cell immunity is highly dependent on the rapid expansion of ef ector cells and subsequent cell survival to form long-lived memory T cells. Proliferation is associated with considerable genomic stress and the activation of DNA damage response pathways, which are increasingly compromised with immune aging (19) . Best known is telomeric erosion, in part due to a cumulative replicative history, in part due to a decline in repair mechanisms, in particular the expression of telomerase (20) . Age-associated telomeric erosion is seen in naïve T cells and more so in CD8 ef ector cells, in which telomerase expression appears to limit clonal expansion (21) . Reduced telomerase expression in naïve CD4 T cells contributes to the accelerated immune aging in rheumatoid arthritis (22) . Nontelomeric DNA damage responses also decline with age. End-dif erentiated CD8 CD28 T cells overexpress miR-24, which down-regulates the expression of histone variant H2AX (17) . As a consequence, DNA damage responses to genotoxic stress are impaired in these cells with reduced serine phosphorylation of ataxia telangiectasia mutated (ATM) and p53. Also, naïve CD4 T cells from patients with rheumatoid arthritis have reduced expression of the ATM-MRE complex, which causes increased frequencies of DNA double-strand breaks and impaired p53 activation in T cells from these patients (23) . Functional consequences are increased apoptosis susceptibility and a decreased replicative capacity, which dampens T cell responses.
When looking at local T cell responses, such as in mucosal or skin barriers, age-related impaired responsiveness is also evident (24) . A prototypical T-dependent skin reaction, cutaneous delayed type hypersensitivity (DTH) in response to recall antigens, is strongly decreased in older individuals. However, this is not due to defective T cell functions but rather to inadequate activation of dermal blood vessel endothelial cells that do not allow extravasation of memory T cells and their entry into the skin. T is is due to inability of tissue macrophages to release the endothelial cell activator tumor necrosis factor-α (TNF-α) upon challenge. However, isolated cutaneous CD163 + macrophages from old subjects can secrete TNF-α af er stimulation with TLR ligands in vitro, indicating that there is no intrinsic macrophage defect. T e increased presence in old skin of CD4 + Foxp3 + regulatory T cell (T reg cells) (25) is possibly responsible for shif ing macrophage functional programming toward M2 (deactivation, antiin+ ammation), reducing their capacity to produce TNF-α (26) .
B cell responses. Impaired humoral responses in older people may be caused in part by a reduced B cell repertoire ( Fig. 1 ) (27) . A comparison of the antibody responses to winter vaccination (+ u+pneumococcus) of two age groups (<50 and >65 years) has demonstrated that older individuals have reduced serum immunoglobulin M (IgM) and IgA pneumococcal responses, although they have no dif erence in IgG levels. Repertoire analysis (performed with CDR3 spectratyping) showed a clear change in the repertoire at day 7 af er vaccination with a return to the baseline levels at day 28 in younger individuals, whereas these changes were much less evident in older people. In particular, changes in the IgA repertoire were quite substantial, with little amplif cation at day 7 and no complete return to baseline at day 28. In particular, IgA1 levels were + at in old individuals, although they increased and then decreased in younger people. Overall, the antibody response to the vaccine of the older group comprises antibody subclasses characteristic of Tindependent types of responses, as opposed to the younger group (28) .
IMPROVING IMMUNE RESPONSE IN THE ELDERLY
What can we do for improving the immune reactivity of the elderly, decreasing the infection burden? Physical exercise is strongly recommended. It has been demonstrated that moderate physical exercise greatly improves the immune reactions of elderly people-for instance, by inducing much better protective antibodies af er in+ uenza vaccination (29) . Moreover, vaccines are one of the most cost-ef ective health interventions and have proven to be crucial in preventing mortality and morbidity linked to a large number of pathogens. Sustained protection against infectious diseases, not only in childhood but also in adulthood and in older ages, should become a goal of a comprehensive global health program.
Systematic information on infections in the aged populations and data on aging immune responses are needed to guide program development. Although most available data are mostly collected in the high-income countries of the world, the middle-and low-income settings remain largely undocumented. T e World Health Organization (WHO), through a joined ef ort of their aging and life-course (ALC) and immunization departments (IVB/IVR), is developing a research agenda on the use of vaccines and immunization during the life course of an individual, which could eventually result in increased quality of life and substantial savings to the health system. Developing such a research agenda requires combining f ndings on populations and gerontology with immunology and molecular biology, to generate knowledge that eventually will lead to policy for the vaccination of groups beyond infancy. Data will be collected in populations of dif erent ages and of dif erent areas of the world, so the information generated can lead to global policy. As a f rst step, WHO has prioritized epidemiology and disease burden, immunological status/immune senescence and related methodology, implementation/ programmatic research with selected vaccines, and socioeconomic analysis to assess and compare benef ts of dif erent interventions. A global systematic review of disease burden (such as respiratory infections), with emphasis on morbidity throughout the life of an individual has been initiated, and methodology to assess the immunological status (such as T cell status) of a major collection of dried blood samples (several thousand samples) from individuals from all regions of the world and of dif erent ages is being validated. T e immediate next step will be to apply the measurement to a representative part of the collection in order to assess the ef ective resting naïve T cell pool (a marker of aging).
IMPROVING VACCINE EFFICACY IN THE ELDERLY
One key strategy to improve immune response in the elderly is vaccination. Strategies to better protect the elderly may include vaccination at younger ages, when the immune system is fully competent. An additional interesting approach might be vaccination against pathogens, such as CMV, which have been implied in the induction of immunosenescence, and/or at improving the durability of immunological memory. T e possibility to protect against CMV and to induce long-lasting memory thanks to vaccine by using strong adjuvants may open the way to such approaches (30, 31) . A very interesting example of immune senescence due to infection is that of chronically infected HIV-1 patients (32)
CD28
-memory T cells, or a huge increase in CMV-specif c cells). T us, preventive strategies that will be designed for elderly people may apply to HIV patients and vice versa.
TAILORED VACCINES FOR THE ELDERLY
One approach to vaccinating elderly populations is to develop new vaccines that target diseases af ecting elderly subjects. Several diseases preferentially af ect the elderly population. For instance, infection with Clostridium dif cile (the most frequent cause of nosocomial diarrhea) causes considerable problems in most industrialized countries because available treatments are suboptimal, with the elderly population being at an increased risk of infection-related morbidity and mortality. Any vaccine would need to be tailored to the responsiveness of the aged population that, at variance with younger adults, responds only to toxin A and not to toxin B or their combination (33) .
Another approach would be to adapt existing vaccines to the elderly. T e suboptimal ef cacy of some vaccines in an elderly population may result from the age-related impairment of immune functions, as discussed above, but also to the increase in comorbidities. It is therefore important to redesign existing vaccines in order to improve their ef cacy in the aged, immunological frail population. Changes in the vaccination schedule, vaccine dose, route of immunization, as well as combination with an adjuvant or administration of a biological response modif er have been attempted without impressive results (34) . In the case of anti-in+ uenza vaccination, the intradermal inoculum appeared to yield a small imon May 16, 2013 stm.sciencemag.org Downloaded from provement, both in the elderly and in people with chronic diseases (35) . Approaches to counterbalancing the ef ects of immunosenescence (such as by improving the BMI) can also increase the response to vaccination (36) .
T ird, vaccination coverage needs to be improved. Taking tetanus vaccination coverage as an example, several surveys indicate that vaccine coverage (measured as protective antibody titers) is incomplete and that an important percentage of elderly people does not have protective anti-toxin antibody levels. For instance, a recent study in Turkish farmers over 50 years of age reported detection of a seroprotective tetanus antitoxin level in only 34% of study participants, which fell to 9.5% in people >70 years of age (37) . In the United States, only 31% of the >70-year-old population is covered (38) . Although the disease is nowadays very rare, it is notable that the highest percentage of tetanus infections (30.5%) in the United States in the period from 2001 to 2008 (197 cases with known outcome) occurred in the age group >65 years, and that in the same age group occurred also the major part of the fatal cases (20 of the 26 deaths) (38) . Better vaccine coverage is therefore urgently needed to reduce the occurrence of vaccinepreventable diseases in the elderly.
Improving vaccine ef cacy with adjuvants. One way to improve vaccine ef cacy in aged populations is with adjuvants. Adjuvants have been used in human vaccination since the 1930s, with the introduction of alum, but only recently has a new class of adjuvants been registered for human use. Oil-in-water adjuvants (such as MF59 and AS03) have given excellent results so far in improving immune responsiveness in elderly individuals to in+ uenza vaccines (both seasonal and pandemic in+ uenza vaccines) and in vaccination against other microbial agents. Seasonal + u vaccination with MF59 in the elderly acts as a boost (because the recipient is not naïve) and induces substantial increase in the titer of specif c antibodies, but it also enhances the repertoire of B cell epitopes recognized. Much knowledge has been recently acquired on the early immunological events triggered by MF59 (39, 40) .
T e mechanisms by which adjuvants rescue immune responsiveness in the elderly are being actively investigated and involve the controlled triggering of local innate/in+ ammatory events that then inform a potent adaptive immune response. T e in+ ammation-related side ef ects that are attributed to vaccine adjuvants are the focus of major efforts in safety investigation. T e recent cases of narcolepsy in children af er + u vaccination with AS03-adjuvanted pandemic in+ uenza vaccine in countries such as Sweden (41), Finland (42) , and the United Kingdom (43) never occurred in elderly people or at any age when using other adjuvants, such as MF59. Although the precise causes of the narcolepsy events are not yet fully clarif ed, it should be noted that a similar incidence of narcolepsy cases have occurred also in China af er administration of nonadjuvanted vaccine, and it correlated with the presence of concurring bacterial lung infection (44) . A deeper understanding of the mechanisms of adjuvant-induced amplifying ef ects is required to better tune the development of stronger vaccine responses in immunologically frail elderly individuals.
NEW TECHNOLOGIES FOR IDENTIFYING SUBTLE IMMUNOLOGICAL CHANGES
A major issue in further def ning and responding to immune senescence is that changes that distinguish normal immune reaction from inadequate responsiveness can be so subtle that their identif cation may be elusive. New technologies are being developed and becoming available to researchers that provide multiparametric, high-throughput evaluation of dynamic immune cell behavior and allow identif cation of the slightest anomalies (Fig. 2) .
Proteomic analysis. An example of a new technology for assessing the cellular protein prof les is mass cytometry [cytometry by time-of-+ ight mass spectrometry (Cy-TOF)], a recently developed technology in which + uorochromes are replaced with heavy metal isotopes. T e quantity and mass of the stable isotopes are detected by means of an inductively coupled plasma mass spectrometer (ICP-MS), which currently allows for the analysis of spectra encompassing 100 isotope channels at an acquisition rate of 500 cells per second. T e high resolution of the time-of-+ ight (TOF) mass analyzer used in the mass cytometer, combined with the intrinsically discrete nature of isotopic masses, allows the perfect discrimination of isotopes 
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separated by only one atomic mass unit, with negligible spectral overlap. T is very high resolution dramatically increases the number of parameters that can be measured simultaneously per single cell, especially when compared with + uorochrome-tagged reagents. T e application of CyTOF to immunophenotyping bone marrow and peripheral blood mononuclear cells of healthy individuals has allowed the simultaneous evaluation of at least 34 distinct parameters at the single-cell level (45, 46) . T e singlecell data from such studies may represent the reference against which immunological variations in the elderly can be identif ed. Data analysis with the sof ware SPADE allows visualization of data clustering in a twodimensional (2D) tree structure (47) .
As an example of possible applications of CyTOF-based high-content screening, a 36-parameter study of CD8 + cytotoxic T cells has allowed the quantitative identifcation of dif erent subsets specif c for Epstein-Barr virus, CMV, and in+ uenza, and the simultaneous characterization of their subcellular complexity in terms of plasma membrane markers, intracellular cytokines, and granule components (48) . It is reasonable to expect that the possibility of measuring a greatly enhanced number of parameters at the single-cell level, because it is made possible by mass cytometry, will af ord new opportunities for improving immunological prof ling, diagnosis, and preventive/therapeutic intervention and will allow to evaluate how age and concomitant conditions af ect the immunological parameters normally triggered by infections and/ or by vaccination.
Systems biological approaches. Another new approach for assessing the immunological changes induced by vaccination and their relationship to ef ective protection relies on systems biology methods. T e aim is that of exploiting retrospective information on the mechanisms underlying the ef cacy of successful vaccines (that up to now is evaluated retrospectively upon infection) to understand how vaccines trigger protective immunity and, based on ef cacy-predicting prof ling, implement a new generation of ef ective-by-design vaccines (49) .
T e identif cation of molecular signatures induced rapidly af er vaccination, which correlate with and predict the later development of protective immune responses, represents the initial strategy to prospectively determine vaccine ef cacy, as for instance has been done in the case of the yellow fever vaccine (50) . Such a strategy would be particularly useful when evaluating the ef cacy or immunogenicity of untested vaccines, as well as in identifying individuals with suboptimal responses amongst high-risk populations, such as infants or the elderly (51) .
T e study of a biological system, such as the development of protective immunity, requires a detailed understanding of its constitutive elements but also a holistic understanding of how those elements interact to produce the complex molecular and cellular chain of events that give rise to immune responses. Although available large-scale prof ling platforms can capture the state of entire systems, exploiting this information to gain in-depth understanding of the organization of those systems remains a challenge. To simplify the analysis and interpretation of large-scale data sets, sophisticated computational approaches are being developed. T e resulting modular analysis frameworks can be used to develop novel tools for the assessment of the immune system in largescale human immunology studies. As an example, transcriptomic analysis of blood samples from healthy individuals versus patients with a bacterial infection has allowed the identif cation of signatures not only specif c for the disease but also the disease stage/ activity and the ef ect of therapy (52) . New high-throughput screening platforms can reduce analysis to minimal blood volumes (100 µl) and, together with the advanced computational approaches of modular analysis, simplify complexity so as to bring about data interpretation and classif cation rapidly and in a straightforward fashion.
T is approach has been used to assess the ef ects of aging on the B cell repertoire. Changes in the immunoglobulin repertoire and B cell functional responses in elderly people were examined using high-throughput DNA sequencing to sequence the immunoglobulin heavy chain V(D)J rearrangements. Methodologically, the most complete and reliable results were obtained with the combined use of both genomic DNA and cDNA libraries (run in duplicate) as template, gene-specif c primers, and 454 sequencing (more expensive but providing 500 base pair) that can capture the entire V(D)J in one read (53) . Clonal expansion (as induced by in+ uenza vaccination in adult subjects) does not in+ uence the repertoire diversity. A study with 70 healthy subjects 1 to 88 years old was performed to assess clonal expansion upon in+ uenza vaccination. Some participants were sampled twice 1 year apart. Sequence analysis shows little age-related change in V, D, J segment usage, V-D and D-J junction properties, or complementary determining region 3 (CDR3) features during adult life. Hypermutation frequency of the V genes in the total repertoire was also comparable between adult subjects of various ages. Clonal expansion analysis, however, revealed that limited numbers of large expanded clones are more frequently observed in elderly people than in younger adults. In addition, the large clones in elderly people distinguish themselves from those in younger people in that they appear to persist over time. How this behavior of elderly B cells in response to challenge correlates with chronic viral infection status remains to be elucidated.
T cell responses also depend on the available repertoire of naïve and memory T cells. T cell generation in the thymus dramatically decreases with age, giving rise to the notion that the repertoire contracts with age. Although recent studies have questioned the role of the thymus to maintain T cell homeostasis (54, 55) , increasing oligoclonality is found for CD8 T cells (56) (57) (58) , and an abrupt repertoire contraction has been described for CD4 T cells with older age (59) . More detailed studies using massive parallel sequencing of T cell receptor genes are currently underway. T ese studies will have to be supplemented by functional studies quantifying the precursor pool in the human naïve and memory T cell repertoires that is specif c for a given antigen. One of the newly developed high-throughput cellular screening (HTCS) approaches is based on the polyclonal stimulation and expansion of limiting the number of naïve T cells in multiple replicate cultures with antigen and autologous antigen-presenting cells in order to generate libraries that can be repeatedly screened for the presence of antigen-specif c T cells. As proof of principle, two antigens are used, represented by two dif erent types of microbes, Candida albicans and Staphylococcus aureus. Validation is provided by parallel assessment of T cell repertoire ex vivo from infected patients. Multiparametric + ow cytometry analysis allows detecting the phenotype of T cells and their capacity to produce cytokines during time from priming (in vitro or in vivo). T e HTCS approach allowed the clear distinction of T H 17 memory subsets induced by the two microbes, based on dif erent capacity to produce IL-10 (primed by S. aureus) on May 16, 2013 stm.sciencemag.org Downloaded from versus interferon-γ (primed by C. albicans) (60) . Memory T cell libraries can be used for analyzing the antigen-specif c repertoire, and their cross-reactivity with other antigens (such as C. albicans-specif c memory T cells can recognize other Candida strains and also loosely related Saccharomyces cerevisiae). Methodologically, the 14-parameter + ow cytometric analysis of T cell phenotypes is ef ciently evaluated with the SPADE sof ware that allows the clustering of data into a 2D tree representation of qualitative and quantitative subpopulations (47) . T is HTCS approach can be used to interrogate the T cell repertoires of elderly people in order to assess their memory status and the reactivity to vaccinations.
SPECIFIC PROBLEMS
I n f u e n z a . One specif c concern is the limited ef cacy of in+ uenza vaccines in the elderly. In this population, low ef cacy has been linked to reduced serum antibody responses. To fully understand the mechanisms of decreased antibody production with age, valid and reliable models are needed: Mouse models cannot be used because they do not accurately reproduce the human situation. In humans, investigating the mechanisms underlying the age-dependent fading of immunity should be studied with model antigens to which individuals have never been previously exposed in their life because the previous repeated exposure to the virus can substantially and variably affect the response levels of dif erent individuals. T us, in+ uenza antigens do not represent the most ideal antigens to study immune responses exquisitely triggered by vaccination. Despite these limitations, considerable information can be collected by examining the functions of plasmablasts (B cells in the process of becoming antibodyproducing plasma cells) in cohorts of adults versus elderly people upon vaccination with the in+ uenza vaccines (such as the inactivated 2009 seasonal TIV in+ uenza vaccine or the 2009 monovalent pandemic H1N1 vaccine). By measuring dif erent parameters (the numbers of vaccine-specif c plasmablasts, the quantity of polyclonal antibodies secreted by plasmablasts, and the specif city and af nity/avidity of the secreted antibodies) (61) , it turns out that elderly people develop a lower number of + u-specif c plasmablasts, which produce the same amount of antibodies as young cells, with normal af nity/avidity against variant in+ uenza strains. It is noticeable that the antibodies induced by seasonal + u vaccination in elderly people do strongly recognize the pandemic H1N1 virus, whereas those of young people do not (62) . T us, elderly subjects appear to have a reduced capacity of B cell amplif cation, and their memory B cell repertoire is shaped by the age-associated in+ uenza exposure history, generating a dif erent response pattern.
Pneumococcal disease. T e pneumococcal disease nowadays is restricted to elderly people and risk groups (for example, smokers), with an overall case fatality rate of ~12%. Pneumococcal polysaccharide vaccines have been used for a long time to prevent pneumococcal diseases in the elderly and in risk groups. T eir ef cacy and ef ectiveness has always been controversial. T ere is substantial agreement that the presently used 23-valent polysaccharide vaccine is 50 to 80% ef ective for the prevention of invasive pneumococcal diseases in healthy adult subjects, but it is not ef ective in the elderly because it does not prevent the disease nor the increased mortality due to the disease. Recently, the 13-valent conjugate pneumococcal vaccine has been licensed by the European Medicines Agency for use in subjects aged ≥50 years, with indication against invasive pneumococcal diseases, based on comparative immunogenicity data with the polysaccharide vaccine. Immunogenicity was shown to be always noninferior, and in most instances superior to that of the polysaccharide vaccine for the common serotypes. Ef ectiveness data for the conjugate vaccine are not yet available but are probably awaited by 2013 from a big study of ef ectiveness on community-acquired pneumonia presently underway in the Netherlands. Public health decisions will have to be made in the near future about the best strategy of use for the two vaccines, that will have to take into account the current open questions on immunological, ef ectiveness, ethical, organizational, and communication issues (63) .
Var icella zoster infections. Herpes zoster is caused by reactivation of latent VZV. T cell memory and consequent cell-mediated immunity to VZV (VZV-CMI) prevents latent VZV in sensory neurons from reactivating. VZV-CMI declines greatly with aging, and reactivation occurs more frequently and with more painful outcomes. Specif cally, there is a substantial loss of VZVspecif c CD4 + early ef ectors and CD4 + effector memory cells and lower CD8 + early ef ectors. A vaccine against VZV is available and strongly recommended for elderly people. T e vaccine is able to restore VZV-CMI, although its ef ciency is a function of the age of the vaccinee, and wanes with time (64, 65) . To improve ef cacy, several attempts are underway. Increasing the virus dose in the vaccine and repeated administrations do not yield any appreciable improvement. Studies with adjuvants and a trial with an adjuvanted recombinant glycoprotein vaccine are underway.
CONCLUDING THOUGHTS
T e aging of the population worldwide imposes new agendas in the priorities for research priorities in general and in the f eld of vaccination in particular. Vaccines have been considered up to recently as particular to the pediatric age. However, although young children remain an ideal target for vaccination, diseases that will hit at older ages are gaining increasing importance as the composition of the population changes. (66) . In this respect, prevention of diseases that particularly af ect older age groups acquires a higher and higher prof le and needs dedicated answers. Despite the impressive progress experienced in the past decade in the f eld of immunology, molecular biology, and systems biology, a great body of work still remains to be done to apply this progress in scientif c knowledge to the f eld of aging and of immunosenescence in particular (67) .
